Zymeworks Inc.
NASDAQ:ZYMEBiotechnology
-$0.38 today
- Market cap
- $1.87B
- Beta
- 1.14
- P/E (TTM)
- -16.6
- EPS (TTM)
- -$1.37
Volume 0.99M
Average 0.71M
Returns on capital
Zymeworks Inc. management
Start with the returns management earns on the capital it controls, then review the people, their trades, and growth quality.
Return Metrics
ROE, ROIC & ROA over time
ROE
-30.2%
avg -65.4%
ROIC
-30.1%
avg -37.0%
ROA
-23.4%
avg -29.1%
Analysis
ROA is currently the strongest return metric at -23.4% versus its period average of -29.1%. 0 of 3 return metrics are above their quality threshold, which helps indicate how efficiently the company turns capital and assets into profit.
Leadership
Who runs the company?
Review the executive team, tenure, compensation, and ownership.
Management
Key executives, compensation & ownership
| Name | Title | Compensation | Age | Shares Owned | Ownership % |
|---|---|---|---|---|---|
Kenneth H. Galbraith | Chairman of the Board, Chief Executive Officer & President | USD 1.71M | 64 | — | — |
Paul Moore | Chief Scientific Officer | USD 998.37K | 59 | — | — |
Sabeen Mekan | Senior VP & Chief Medical Officer | — | 46 | 0 | <0.01% |
Stuart Knight | Executive VP & Chief Information Officer | — | — | — | — |
Bijal Desai | Senior Vice President of Finance | — | — | — | — |
Shrinal Inamdar | Vice President of Investor Relations | — | — | — | — |
Lindsey Foulkes | Senior Vice President of Corporate Development & Strategy | — | — | — | — |
Mark Hollywood | Executive VP & Chief Operating Officer | — | 57 | 133.85K | 0.18% |
Paul R. Schneider | Executive VP & General Counsel | — | 55 | 0 | <0.01% |
Laura O'Connor | Senior VP & Chief Human Resources Officer | — | — | — | — |
Scott Platshon | Executive VP & Chief Business Officer | — | 35 | 0 | <0.01% |
Diana Papove | Vice President of Corporate Communications | — | — | — | — |
Kristin Stafford | Executive VP & CFO | — | 44 | 50.00K | 0.07% |
Compensation is shown in the reported currency; data updated Nov 7, 2026.
Ownership uses each executive's latest SEC Form 4 holding only when the full name maps to one reporting CIK; latest matched holding Jul 6, 2026.
Insider trading
Are insiders buying or selling?
Follow recent insider purchases and sales reported on Form 4.
Insider Trading
SEC Form 4 transactions — last 12 months
Buys
0
$0.00
Sells
11
$5.03M
Net Transaction Value
−$5.03M
Net selling
Most Active
Galbraith Kenneth
4 transactions
Transactions sorted by date, descending.
| Type | |||
|---|---|---|---|
| Oct 9, 26Oct 9, 2026 | Schayowitz Adam Direct | Sell | $357.6K$357,557.20 |
| Jan 12, 26Jan 12, 2026 | Hollywood Mark Direct | Sell | $138.8K$138,761.82 |
| Jan 12, 26Jan 12, 2026 | Smith Jeffrey T L Direct | Sell | $211.1K$211,090.29 |
| Jan 12, 26Jan 12, 2026 | Moore Paul Andrew Direct | Sell | $216.8K$216,758.66 |
| Jan 12, 26Jan 12, 2026 | Galbraith Kenneth Direct | Sell | $689.8K$689,818.56 |
| Jan 5, 26Jan 5, 2026 | Moore Paul Andrew Direct | Sell | $271.6K$271,573.55 |
| Jan 5, 26Jan 5, 2026 | Moore Paul Andrew Direct | Sell | $233.1K$233,125.10 |
| Jan 5, 26Jan 5, 2026 | Galbraith Kenneth Direct | Sell | $795.2K$795,220.37 |
| Jan 5, 26Jan 5, 2026 | Galbraith Kenneth Direct | Sell | $568.6K$568,620.46 |
| Jan 5, 26Jan 5, 2026 | Smith Jeffrey T L Direct | Sell | $264.5K$264,471.13 |
1–10 of 11
Summary
Insiders reported 0 buys worth $0.00 and 11 sells worth $5.03M over the last 12 months. That adds up to net selling of $5.03M. Galbraith Kenneth was the most active insider with 4 transactions.
Growth analysis
Is management growing the business?
Compare historical growth with analyst forecasts across revenue, earnings, and cash flow.
Growth Analysis
Historical CAGR & forward analyst estimates
| Metric | 10yr | 5yr | 3yr | Fwd Est. |
|---|---|---|---|---|
| EPS | N/A | N/A | N/A | N/A3 analysts |
| Revenue | N/A | N/A | -36.4% | +36.2% (5yr)5 analysts |
| Net Income | N/A | N/A | N/A | N/A5 analysts |
| EBIT | N/A | N/A | N/A | N/A5 analysts |
Analysis
Recent growth has been strongest in Revenue at -36.4% over three years. Forward estimates point to Revenue at +36.2% (5yr), giving you a quick check on whether expectations are accelerating or cooling.
Competitors
Who does Zymeworks Inc. compete with?
Open similar companies to compare how their management teams allocate capital.
Questions
Management questions
Common questions about ZYME's management, answered from reported figures.
Who manages ZYME?
Zymeworks Inc. (ZYME) lists 13 active executives. The top listed executive is Sabeen Mekan, Senior VP & Chief Medical Officer.
Are ZYME insiders buying or selling?
Recent insider activity shows net buying of $102.50M.
Continue the stock analysis
Jump to another research area for this company.